Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-303

I'll answer this.

If the IDMC recommended to reduce the trial size because of good results (which is an extremely rare event) effectively costing you less for the trial and looking after shareholders in the process, wouldn't you?

The interim results obviously were good.
As time went on, unfortunately the Hazard Ratio numbers increased to 0.71 from 0.418 I believe.

The trial design will be different, in fact 3 different ones to see the best way forward. They could all be fantastic, for all we know a big pharma company may have said "here, try this one, pair it with Hervaxx, you fund the trial and if it compliments our drug, we will license it from you".

That's my take on this and quite possible.

Our management hasn't let us down in recent history.
We are in good hands. They've got a lot of skin in the game too, especially LC.